

Efforts to Support Organic Growth through Inorganic Initiatives

M&A Strategy and Policy

Olympus’ Business Development team is responsible for identifying and pursuing M&A, partnership, and investment opportunities that align with our company strategy. We continue to enhance our product portfolio through growth-accretive, tuck-in M&A opportunities in our priority businesses of GI, Urology and Respiratory. Business development projects, whether M&A, partnership, or investment, are intended to drive growth and provide an important complement to our organic innovation efforts.

Co-founding Swan EndoSurgical to Advance Endoluminal Robotics

Olympus has partnered with Revival Healthcare Capital to create a new company, Swan EndoSurgical. This strategic action aims to accelerate the development of endoluminal robotics and deliver innovative medical solutions, with an initial focus on GI treatments.

We estimate that the market size for endoluminal robotic surgery in the U.S. alone could reach over USD 2 billion by 2040. This partnership is part of Olympus’ strategy to strengthen our position as a global MedTech company and expand our presence in important and long-term growth markets. Endoluminal robotics has the potential to contribute to the widespread adoption of minimally invasive endoscopic procedures, improve medical outcomes, and ultimately enhance health and well-being for more patients. Olympus has been actively investing in this field through in-house research and development as well as investments in startups, and this will also continue.



Our Vision for the Future

- Accelerating Innovation and Market Entry
- Transforming Patient Outcomes
- Scalable Platform for Broader Applications

Olympus Innovation Ventures

Olympus Innovation Ventures

Olympus Innovation Ventures (OIV) was launched in 2021 as the corporate venture capital arm of Olympus. OIV invests in early-stage companies that complement or extend our market-leading solutions in GI, Urology and Respiratory areas. OIV partners with innovative entrepreneurs to strengthen Olympus’ market leadership by operating at the forefront of market trends, gaining access to new innovations, as well as identifying potential partners and acquisition targets. Recent investments in a diverse portfolio of companies are as below, demonstrating our strong commitment to inorganic growth through investment, partnership and acquisition.

Our Portfolio—Main Products/Services

Virgo Surgical	AI for endoscopy video capture and analysis
Alimetry	Medical device aiding informed diagnostics of gastric function
Eximis Surgical	Next-generation, minimally invasive surgery specimen segmentation and removal solution
Neuspera Medical	Ultra-miniaturized sacral neuromodulation implant
Neptune Medical	Proprietary technology that allows for the instant transformation of flexible tubes into rigid structures applied to GI endoscopy
On Target Laboratories	Intraoperative medical imaging agents to fluoresce cancer
Universal Diagnostics	Liquid biopsy dedicated to early detection of colorectal cancer

Note: Investments by OIV and Olympus Corporation of the Americas

OIV also champions our collaboration with MedTech Innovator (MTI), the preeminent global medical technology accelerator. OIV works with MTI to select annual cohorts of innovative startups building next-generation medical devices.

MedTech Innovator



MedTech Innovator is the world’s largest accelerator for medical technology startups. Annually approximately 1,500 global companies apply to participate in MTI’s flagship four-month program designed to de-risk innovation and accelerate the path to U.S. market success. OIV works with MTI to review, select and mentor cohorts of next-generation medical device, diagnostic and digital health companies. MTI partnership provides access to new innovations and investment opportunities.